

Gluten-free Food Insecurity in Pediatric Celiac Disease

Andrew Krueger, MD; Lin Fei, PhD, MS; Emrah Gecili, PhD; Adrienne Henize, JD; Andrew Beck, MD, MPH; Melissa Klein, MD MED; Daniel Mallon, MD, MSHPEd.



Introduction

Increase in prevalence of food insecurity (FI) among households with children from

12.5% in 2021 ➔ 17.3% in 2022

Food Insecurity ≠ Nutritional Insecurity

Nutritional insecurity exists when there is inconsistent and/or unequal access to “healthy, safe, and affordable foods that promote optimal health and well-being”

Celiac Disease (CeD) requires lifelong adherence to a gluten-free diet (GFD)

Gluten-free (GF) foods in the US cost **183%** more compared to wheat-based alternatives

Methods

- Patients <18yo with CeD diagnosis and seen by a Cincinnati Children's Hospital Medical Center gastroenterologist between 11/1/2018 and 11/1/2024 were invited to participate
- Electronic survey was sent to all mobile phone numbers and emails listed in the patient's electronic health record (EHR) four times
- Sociodemographic and clinical data extracted from EHR

Survey Instrument

- US Household Six-Item Short Form Food Security Survey Module
- Adapted Hunger Vital Sign™ to assess GF FI
- Gluten-Free Eating Assessment Tool short to assess for GFD adherence
- Questions assessing social determinants of health as barriers to GFD adherence
- Demographic information



Classified by food security status


	Gluten-free Food Insecure	Gluten-Free Food Secure
General Food Insecure	GF FI/FI	GF FS/FI
General Food Secure	GF FI/FS	GF FS/FS

Results


1039 patients from 994 unique households (43 households with multiple CeD patients) received survey invitations

34.8% (346/994) response rate

General Food Insecurity Prevalence



Gluten-free Food Insecurity Prevalence




Results of group comparisons to examine associations between food security status and sociodemographic characteristics

	GF FI	GF FS	p-value	GF FI/FI	GF FI/FS	p-value	GF FI/FS	GF FS/FS	p-value
Deprivation Index Score									
Mean ± Standard Deviation	0.28 ± 0.1	0.24 ± 0.08	0.0006	0.29 ± 0.1	0.27 ± 0.09	0.35	0.27 ± 0.09	0.24 ± 0.08	0.13
Health Insurance Type (n, %)									
Public	21 (24.1)	17 (6.7)	<.0001	18 (32.1)	3 (9.7)	0.019	3 (9.7)	17 (7)	0.59
Private	64 (73.6)	234 (92.5)		36 (64.3)	28 (90.3)		28 (90.3)	225 (92.2)	
Self-pay	2 (2.3)	2 (0.8)		2 (3.6)	0 (0)		0 (0)	2 (0.8)	
Total Household Income (n, %)									
Less than \$60,000	29 (34.5)	10 (4.2)	<.0001	26 (46.4)	3 (10.7)	0.0092	3 (10.7)	8 (3.5)	<.0001
\$60,000 - \$105,000	27 (32.1)	40 (16.7)		13 (23.2)	14 (50)		14 (50)	39 (17)	
\$105,000 - \$150,000	20 (23.8)	53 (22.1)		12 (21.4)	8 (28.6)		8 (28.6)	49 (21.3)	
Greater than \$150,000	8 (9.5)	137 (57.1)		5 (8.9)	3 (10.7)		3 (10.7)	134 (58.3)	

Results of group comparisons to examine associations between food security status and gluten-free dietary adherence and barriers

	GF FI	GF FS	p-value	GF FI/FI	GF FI/FS	p-value	GF FI/FS	GF FS/FS	p-value
Gluten-free dietary adherence (n, %)									
Frequent gluten (>1x/week)	8 (8.9)	5 (2.1)	0.0004	6 (10.5)	2 (6.1)	0.091	2 (6.1)	3 (1.3)	0.29
Occasional gluten (1-4x/month)	10 (11.1)	5 (2.1)		8 (14)	2 (6.1)		2 (6.1)	5 (2.1)	
Rare intentional gluten (<1x/month)	7 (7.8)	7 (2.9)		5 (8.8)	2 (6.1)		2 (6.1)	7 (3)	
Rare accidental gluten (<1x/month)	30 (33.3)	97 (40.1)		19 (33.3)	11 (33.3)		11 (33.3)	95 (40.4)	
No known gluten	35 (38.9)	128 (52.9)		19 (33.3)	16 (48.5)		16 (48.5)	125 (53.2)	
Reported gluten-consumption due to increased cost of gluten-free foods at grocery (n, %)									
Yes	17 (19.3)	1 (0.4)	<.0001	14 (25.5)	3 (9.1)	0.060	3 (9.1)	1 (0.4)	0.0064
No	71 (80.7)	240 (99.6)	41 (74.6)	30 (90.9)	30 (90.9)		233 (99.6)		
Reported gluten-consumption due to increased cost of gluten-free foods while eating outside of the home (n, %)									
Yes	22 (24.7)	1 (0.4)	<.0001	18 (32.1)	4 (12.1)	0.034	4 (12.1)	1 (0.4)	0.0009
No	67 (75.3)	240 (99.6)	38 (67.9)	29 (87.9)	29 (87.9)		233 (99.6)		
Reported gluten-consumption due to transportation barriers (n, %)									
Yes	7 (7.9)	5 (2.1)	0.019	4 (7.1)	3 (9.1)	0.71	3 (9.1)	4 (1.7)	0.042
No	82 (92.1)	237 (97.9)		52 (92.9)	30 (90.9)		30 (90.9)	231 (98.3)	
Reported gluten-consumption due to lack of accessibility of gluten-free food at nearby locations (n, %)									
Yes	22 (25)	20 (8.3)	<.0001	17 (30.4)	5 (15.6)	0.12	5 (15.6)	19 (8.1)	0.18
No	66 (75)	221 (91.7)		39 (69.6)	27 (84.4)		27 (84.4)	215 (91.9)	
Reported gluten-consumption due to personal choice and/or preference (n, %)									
Yes	28 (31.5)	28 (11.6)	<.0001	19 (33.9)	9 (27.3)	0.51	9 (27.3)	25 (10.6)	0.021
No	61 (68.5)	214 (88.4)		37 (66.1)	24 (72.7)		24 (72.7)	210 (89.4)	
Reported gluten-consumption by accident (n, %)									
Yes	61 (67.8)	128 (52.9)	0.015	39 (68.4)	22 (66.7)	0.86	22 (66.7)	124 (52.8)	0.13
No	29 (32.2)	114 (47.1)		18 (31.6)	11 (33.3)		11 (33.3)	111 (47.2)	

Serologic Findings with Tissue Transglutaminase Immunoglobulin A (TTG IgA)



Based on Kaplan-Meier survival curves, gluten-free food insecure respondents took significantly longer for TTG IgA to normalize


- No significant difference in comparing time to normalization of TTG IgA for
 - GF FI/FI vs GF FI/FS
 - GF FI/FS vs GF FS/FS

No significant difference among the three group comparisons in:

- Highest ever TTG IgA
- Proportion of respondents who ever had TTG IgA normalization
- The highest TTG IgA expressed as multiples of the upper limit of normal as a continuous variable

Results

Reasons for gluten-free food insecurity provided by respondents



Conclusions

- One-fourth of survey respondents classified as gluten-free food insecure, higher than general FI rates
- Respondents who identified as gluten-free food insecure had worse adherence to a gluten-free diet
- Patients with gluten-free food insecurity were slower to normalize TTG IgA, but ultimately normalize proportional to those who are gluten-free food secure

Next Steps

Gluten-Free Food Insecurity Recognition and Support (GF FIRST)

- Enhance approaches to clinic-based screening to effectively identify CeD patients with GF FI
- Implement a standardized and sustainable response pathway to address GF FI
- Assess GF FI prevalence and characteristics of GF FI families as identified through in-clinic screening